Krystal Biotech Inc KRYS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
-
Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
-
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
Trading Information
- Previous Close Price
- $175.93
- Day Range
- $175.81–179.45
- 52-Week Range
- $93.95–219.34
- Bid/Ask
- $176.98 / $177.13
- Market Cap
- $5.09 Bil
- Volume/Avg
- 120,468 / 258,450
Key Statistics
- Price/Earnings (Normalized)
- 129.22
- Price/Sales
- 31.33
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 229
- Website
- https://www.krystalbio.com
Comparables
Valuation
|
Metric
|
KRYS
|
RCKT
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 129.22 | — | 15.15 |
Price/Book Value | 6.06 | 3.88 | 2.78 |
Price/Sales | 31.33 | — | 6.69 |
Price/Cash Flow | 115.35 | — | 14.35 |
Price/Earnings
KRYS
RCKT
UTHR
Financial Strength
|
Metric
|
KRYS
|
RCKT
|
UTHR
|
|---|---|---|---|
Quick Ratio | 9.23 | 7.42 | 3.92 |
Current Ratio | 9.50 | 7.79 | 4.35 |
Interest Coverage | — | −143.43 | 22.67 |
Quick Ratio
KRYS
RCKT
UTHR
Profitability
|
Metric
|
KRYS
|
RCKT
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | 8.90% | −41.09% | 16.95% |
Return on Equity (Normalized) | 9.45% | −46.72% | 20.53% |
Return on Invested Capital (Normalized) | 5.64% | −47.69% | 16.62% |
Return on Assets
KRYS
RCKT
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lblhlpzmc | Fwr | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rnfsstnj | Mblyss | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zxjsnffvf | Cwttwg | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xsgstsbr | Xvnqqlh | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Zzfxcxcs | Skc | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Mhxvfvpd | Tlb | $29.2 Bil | |||
| Moderna Inc
MRNA
| Gchqzrps | Lzzjq | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Skwhlppmg | Ftydj | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ytyqmsrtp | Pfqqgpd | $13.2 Bil | |||
| Incyte Corp
INCY
| Pyqwfpkz | Gfqxyvt | $13.0 Bil |
United States